Please login to the form below
Solymbic
This page shows the latest Solymbic news and features for those working in and with pharma, biotech and healthcare.
Amgen wins European approval for Humira biosimilar Amgevita
Meanwhile, in Europe Amgen’s new product has a duplicate marketing authorisation under the brand name Solymbic.
Latest news
-
Merck confirms sale of biosimilar division
In January, the EMA's Committee for Medicinal Products for Human Use (CHMP) backed approval of the Humira biosimilar under two brand names - Amgevita and Solymbic – with approval expected in the
-
Amgen's Humira biosimilars backed for EU approval
Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster. AbbVie's Humira (adalimumab) looks set to be on the defensive in Europe as well as the US this year, after the ... Amgen's biosimilars - Amgevita (ABP 501) and Solymbic - were recommended
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Planting the Seeds for Future Women Leaders in Medicine
- FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours
- GSK shares positive phase 3 results for Blenrep combination in multiple myeloma
- Stem cell therapy trial shows promising results for treating progressive MS
- Cancer Research UK calls on government to create ten-year cancer plan
- Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients
No results were found
PMHub
Kardex
Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
